Anti-vascular endothelial growth factor therapy for ocular diseases of neovascularization

Anti-vascular endothelial growth factor therapy for ocular diseases of neovascularization - Anti-VEGF therapy for ocular neovascularization

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027243

Enrollment

Registered

2017-05-04

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinopathy of prematurity neovascular glaucome vasoproliferative tumor choroidal neovascularization

Interventions

Intravitreal injection of Bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The presence of active ocular neovascularization.

Exclusion criteria

Exclusion criteria: 1, high risk of stroke infarction 2, high risk of myocardial infarction 3, ocular infection

Design outcomes

Primary

Measure	Time frame
Change of ocular blood flow at 1 week, 1 months and 3 months from the initial treatment.	—

Countries

Japan

Contacts

Public ContactTadashi Matsumoto

School of Medicine Toho University Department of Ophthalmology

matsu-t@med.toho-u.ac.jp81-3-3762-4151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026